

Q1  2020
QUARTERLY REPORT

DIGNITANA
Clinically superior scalp cooling



**Growth of 23 percent
as demand for
DigniCap increases**

DIGNITANA AB IS A SWEDISH MEDICAL TECHNOLOGY COMPANY THAT PRODUCES AND MARKETS THE DIGNICAP SCALP COOLING SYSTEM TO MINIMIZE HAIR LOSS DURING CHEMOTHERAPY AND IMPROVE WELL-BEING AND QUALITY OF LIFE FOR CANCER PATIENTS.

Growth of 23 percent as demand for DigniCap increases

Financial highlights

- Group revenue amounted to 12 478 TSEK (10 106 TSEK), an increase of 23 percent over the same period in 2019 and an increase of 24 percent over Q4 2019.
- EBITDA amounted to -8 761 TSEK (-2 799), a change of 213 percent over the same period in 2019 and an improvement of 23 percent compared to Q4 2019.
- Earnings per share is -0.23 SEK compared to -0.11 SEK in the same period 2019.
- Average Daily Treatment Revenue (ADTR)* increased to 118 TSEK (88 TSEK) an increase of 35 percent over the same period in 2019 and an 8 percent increase over Q4 2019.

Business highlights

- An Extraordinary General Meeting was held 10 February 2020 which resolved on one issue, the transfer of warrants to key persons in Dignitana Inc. in accordance with the proposal by the Board of Directors.
- Sponsorship of U.S. events with Susan G. Komen®, the largest breast cancer advocacy non-profit in the world.
- Signed distribution agreement with MedPhy Technologies in India to enable access to this important and growing market.
- Launched DigniCap Mobile App for patient-centered care.

Significant events after the period

- The Company obtained an unsecured loan in the amount of \$353 800 USD from the Payroll Protection Program, a COVID-19 economic stimulus initiative in the United States.
- With the final \$500 000 USD received after the period, funding was completed for the new loan received from Union Business Leasing in the total amount of \$1,5 million USD.
- Dignitana signed a master contract with Hartford HealthCare in the U.S.
- The Company signed a master contract in the U.S. with American Oncology Network.
- Dignitana signed contracts for 5 new locations with U.S. medical providers.

Key Figures

DIGNITANA GROUP	Q1 2020	Q1 2019	Full year 2019
Net revenues, TSEK	11,393	9,237	40,699
Total revenues, TSEK	12,478	10,106	42,546
Net profit after financial items, TSEK	-12,755	-5,270	-37,950
Cash and bank balances, TSEK	8,768	21,715	19,433
Earnings per share before and after dilution, SEK	-0.23	-0.11	-0.76
Average Daily Treatment Revenue*, TSEK	118	88	107

* ADTR includes pay-per-treatment revenue from patients and facilities. Does not include lease revenue or disposable sales.

"Through these unprecedented times we are finding new ways to do business. Cancer doesn't stop for a pandemic, and neither do we."

William Cronin, CEO Dignitana AB

Growth of 23 percent as demand for DigniCap increases

The first quarter of 2020 represented yet another solid step forward for Dignitana with the group registering a 23 percent growth rate over the same period last year and a 24 percent growth rate over the fourth quarter of 2019. The Company shipped 78 DigniCap Delta units during Q1, bringing the total to 218 devices delivered globally since the first DigniCap Delta came off the production line in July 2019. The new device has been very well received by patients and clinicians and our list of pending installations is evidence of the growing demand for DigniCap Delta.

Complementing our U.S. growth, the Company placed DigniCap Delta units in Spain, Israel and Italy and signed a new distribution agreement with MedPhy Technologies to introduce DigniCap to the expanding market in India in the first period.

Strong and increasing utilization rates are an important initiative for the Company, providing recurring revenue and demonstrating growing awareness of scalp cooling. Significantly, in our key U.S. market our Average Daily Treatment Revenue (ADTR) continues to increase on both a per unit and per site basis and our ADTR consistently grew through the entire period. Achieving record quarterly revenue was extremely notable as March was also when many healthcare facilities initiated new safety and treatment protocols related to the COVID-19 pandemic. There has been a significant increase in deferred revenue over last year as more patients are now purchasing treatment cards for DigniCap Delta well in advance of the scheduled usage.

In response to the pandemic the Company has initiated a series of measures to ensure we provide the highest level of service possible at the lowest level of risk to employees, patients and clinical partners. We have developed several

digital resources to fully support customers remotely. These will be further enhanced moving forward allowing the Company to perform new installations more efficiently and at a faster pace.

Looking toward the next period, we see that the growth rate in April and May slowed down due to COVID-19 precautions at some facilities. The extent and scope of the revenue impact related to the pandemic remains unclear as the situation is still changing. However, some medical centers are already resuming normal activities and allowing new patients to begin using DigniCap again. While pandemic protocols are ongoing for an unspecified period, at the time of this report we have initiated several new installations supported by our online training program.

The current emphasis on infection control has reminded us how critical it is that we now have disposables as part of our scalp cooling system. The single patient Cooling Wrap represents a significant improvement in patient fit, nursing time and infection control, and we will continue to work with our partners to find innovative ways for patients to access this vital therapy option with minimal disruption to critical workflows.

Through these unprecedented times we are finding new ways to do business. Cancer doesn't stop for a pandemic, and neither do we. With each quarter Dignitana is becoming a more efficient operation and a stronger company and I look forward to our ongoing growth and expansion.



William Cronin, CEO
Dignitana AB



The Company


Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and operations are based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Erik Penser Bank AB is Certified Adviser.

The Company produces the DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat solid tumors from breast cancer as well as those from prostate, ovarian, uterine, lung and other tissues. In 2019 Dignitana received CE Marking and FDA clearance for sales of DigniCap Delta, the next generation scalp cooling device, followed by approvals in Australia and Israel. DigniCap Delta is now available in Australia, Europe, the Middle East, North America and South America.

Business model

The Company has five primary revenue streams: treatment fees from patients (pay-per-treatment using leased machines), machine sales, service agreements, leasing fees and product disposables and supplies. In the United States the largest opportunity for growth is through the pay-per-treatment model. For global markets that do not have the pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies.



The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors. Globally there are over 12 million incidences of solid tumors diagnosed annually, with more than 1.3 million diagnoses occurring in the U.S. each year. Dignitana estimates that 60 percent of these patients are on regimens compatible with DigniCap. Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in women worldwide with over 1.7 million cases of breast cancer diagnosed annually. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers.

To increase awareness of scalp cooling we work strategically with different organizations and interest groups in the cancer care community. Dignitana's sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this. In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world. In the U.S. Dignitana supports legislative initiatives to make scalp cooling readily accessible for all patients.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users.

The Company is currently in discussions to initiate several new studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients.

The DigniCap Scalp Cooling System is currently available in 38 countries. The DigniCap C3 device has been marketed worldwide since 2009. DigniCap Delta received CE Marking in March, U.S. FDA clearance in June and TGA (Australia) clearance in September 2019. The transition to DigniCap Delta is underway with current U.S. customers and the roster of new U.S. customers is growing rapidly. Outside the U.S., DigniCap Delta is now in use in Australia, Italy, Spain, the United Kingdom and Israel.



Financial information and comments

Revenue – Dignitana Group

The first quarter of 2020 reflects the continued transition to the new DigniCap Delta system which was leased to U.S. locations beginning in the third quarter and became available for sale outside of the U.S. in the fourth quarter 2019.

Group revenues are generated by direct sales of systems, pay-per-treatment fees, cap and patient kit sales, leased systems, service agreements and other revenue.

Dignitana Group total revenue and other income during the first quarter 2020 amounted to 12 478 TSEK, which is an increase of 23,5 percent compared to the same period last year.

The increase in year to date revenue is primarily a result of growth in U.S. patient treatments and unit rentals.

Dignitana revenue and costs are comprised of different currencies such as U.S. Dollars, Euros, SEK, and other currencies. Foreign exchange translation differences are found on the Income Statement in Other Income, Other Operating Expenses and Financial Income and Expenses.

Cost of goods sold includes the cost of finished goods sold during the period. Income arising from the sale of goods is recognized when the goods have been delivered and ownership has been transferred to the buyer. In the U.S. market, Dignitana does not sell devices directly to the end customer as various lease models are employed.

Cost of goods sold for the Group increased to 3 999 TSEK for the first quarter of 2020. Gross margin for the first quarter of 2020 and the full year declined from the prior year due to higher maintenance and repair costs associated with the C3 unit and higher installation costs and disposables associated with introduction of the new Delta system in certain international markets. Additionally, freight costs were included in cost of goods sold beginning with the first quarter of 2020. Previously, freight costs have been included in operating expenses.

Profit and Loss – Dignitana Group

Group EBIT for the first quarter was -12 481 TSEK compared to -4 710 TSEK in the same period in 2019. Net profit after financial items was -12 755 TSEK compared to -5 270 TSEK for the same period last year. The decline in EBIT was due to increases in depreciation and amortization expenses associated with increased number of DigniCap Delta units installed in the U.S. in combination with higher operating and personnel expenses associated with the transition to the new Delta system.

Earnings per share for the first quarter of 2020 amount to -0,23 SEK, which is a decrease compared to the first quarter of 2019.



Revenue – Dignitana Parent Company

Dignitana Parent total revenues during the first quarter amounted to 8 831 TSEK which is an increase of 24,6 percent compared to the same period last year.

The increase in revenue is a result of growth in U.S. patient treatments and unit rentals revenues which are allocated to the Parent company in combination with increased revenues for service and maintenance.

Other Income includes foreign exchange gains on accounts receivable and accounts payable and the revenue associated with the sublease of a portion of the Lund office space.

Profit and Loss – Dignitana Parent Company

Cost of goods sold includes the cost of finished goods sold during the period. Income arising from the sale of goods is recognized when the goods have been delivered and ownership has been transferred to the buyer. In the U.S. market Dignitana does not sell the device directly to the end customer as various lease models are employed.

Cost of goods sold for the Parent increased to 1 978 TSEK for the first quarter 2020 primarily due to freight, maintenance and repair costs increase and other adjustments as the company transitions to the new DigniCap Delta system.

For the first quarter of 2020 operating expenses increased from the prior year due to incremental marketing and other expenses associated with the transition and aggressive rollout schedule for the new DigniCap Delta system.

Parent EBIT for the first quarter was -7 321 TSEK compared to -4 937 TSEK in the same period in 2019.

Net profit after financial items was -7 336 TSEK compared to -5 286 TSEK for the same period last year. The decline in both EBIT and Net profit was due primarily to increases in depreciation and amortization expenses associated with the amortization of the development costs for the Delta system and increased number of DigniCap Delta units installed in the U.S. in combination with higher operating expenses associated with the transition to the new Delta system.

Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by a number of factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The nonconclusive list of the Company's risks concerns include but are not limited to: Patents, Key Personnel, Growth, Management, Restructuring, Development Costs, Competitors, Dependence on Individual Customers, Customers, Authorization and Registration, Chemotherapy Without Side Effects, Distributors and Manufacturers, Profitability and Future Capital Needs, Political Risk, Pandemic Risk, Regulatory or Change of Laws, Disputes and Currency Risks.

For a detailed explanation of these risk factors view the 2019 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements". Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Staff

During the first quarter Dignitana had, on average, 24 persons employed.

The share

The total number of outstanding shares is 55 059 155 and earnings per share is - 0,23 SEK.

The share has been listed on Nasdaq First North Growth Market in Stockholm since 30 November 2011 after having been listed at Spotlight Market in Stockholm since June 2009. It is traded under the DIGN ticker. At the Extraordinary General Shareholders meeting in February 2020 it was resolved to issue and transfer warrants to key

persons in Dignitana Inc. in accordance with the proposal by the Board of Directors. If all the warrants outstanding under the 2017/2020 program would be converted in full the total dilution in number of shares and votes is approximately 4,5 percent. Warrants are given free of charge and costs will be incurred in Q2 2020.

Erik Penser Bank is the Company's Certified Adviser.

Largest Shareholders

31 MARCH 2020	HOLDINGS	PERCENTAGE
ADMA FÖRVALTNINGS AB (Greg Dingizian)	14 364 729	26,09 %
FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION	4 557 919	8,28 %
CBLDN-UBS FINANCIAL SERVICES INC (William Cronin & others)	4 245 739	7,71 %
EUROSUND AB (Johan Stormby)	3 078 036	5,59 %
IBKR FINANCIAL SERVICES AG, W8IMY	1 622 573	2,95 %
SKANDIA, FÖRSÄKRINGS (Greg Dingizian & others)	1 586 575	2,88 %
POURSAMAD, AMIR	1 461 067	2,65 %
NORDNET PENSIONS FÖRSÄKRING AB	1 091 055	1,98 %
RÜLF, SEMMY	1 015 058	1,84 %
PERSSON, RUTGER	997 310	1,81 %
TOTAL	34 020 061	61,79 %
OTHER SHAREHOLDERS	21 039 094	38,21 %
TOTAL	55 059 155	100,00 %

Source: Euroclear

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 28 May 2020

Dignitana AB (publ) Board of Directors

Thomas Kelly
Chairman

William Cronin
Board member and CEO

Mikael Wahlgren
Board member and Deputy Managing Director

Greg Dingizian
Board member

Ingrid Atteryd Heiman
Board member

Pontus Kristiansson
Board member

This interim report has not
been audited by the Company auditors.

Income Statement – Dignitana Group, SEK

DIGNITANA GROUP	Q1 2020	Q1 2019	Full year 2019
Operating Income			
Revenue	11 393 082	9 236 624	40 699 211
Own work capitalized	0	0	0
Other income	1 084 564	869 820	1 846 817
Total Operating Income	12 477 646	10 106 445	42 546 028
Cost of Goods Sold			
Goods for Resale	-3 999 058	-2 163 480	-11 559 218
GROSS PROFIT	8 478 587	7 942 965	30 986 810
Expenses			
Operating expense	-10 039 959	-6 070 590	-34 984 714
Personnel expense	-6 650 113	-4 659 636	-21 367 162
Other operating expenses	-550 507	-12 228	-894 891
Total operating expenses	-17 240 579	-10 742 453	-57 246 767
Operating profit (loss) – EBITDA	-8 761 992	-2 799 488	-26 259 957
Depreciation of tangible and intangible assets	-3 719 458	-1 910 581	-10 266 997
Operating profit (loss) after depreciation – EBIT	-12 481 449	-4 710 070	-36 526 954
Result from financial investments			
Interest income and similar items	42 472	838	102 590
Interest expenses and similar items	-316 292	-560 508	-1 525 440
Total income from financial investments	-273 820	-559 670	-1 422 850
Net profit after financial items	-12 755 269	-5 269 740	-37 949 804
Corporate Taxes	0	-51 123	-85 413
Results for the Period	-12 755 269	-5 320 863	-38 035 217

Balance Sheet – Dignitana Group, SEK

DIGNITANA GROUP	Q1 2020	Q1 2019	Full year 2019
ASSETS			
FIXED ASSETS			
<u>Intangible assets</u>			
Capitalized expenses for development, net	21 093 580	20 837 601	22 594 795
<u>Tangible assets</u>			
Equipment, tools and installations, net	27 758 487	13 779 388	22 214 084
Total Fixed Assets	48 852 068	34 616 989	44 808 879
CURRENT ASSETS			
<u>Inventories and similar</u>			
Finished goods and goods for resale	6 066 284	6 350 621	9 391 105
Advance payment to suppliers	2 798 327	0	0
<u>Current Receivables</u>			
Accounts Receivable	4 969 771	7 469 009	4 409 995
Current Receivables from group companies	0		
Current Tax Assets	327 651	6 825	269 467
Other Current Receivables	1 370 037	348 063	844 666
Prepaid expenses and accrued income	1 430 367	959 557	2 331 781
Cash and Bank Balances	8 768 198	21 715 092	19 432 901
Total Current Assets	25 730 634	36 849 168	36 679 915
Total Assets	74 582 702	71 466 157	81 488 794
EQUITY AND LIABILITIES			
Equity			
<u>Restricted equity</u>			
Share Capital			
(55 059 155 shares par value SEK 1, previous year 40 528 224)	55 059 155	48 599 155	55 059 155
Unregistered share capital	0	0	0
Fund for development expenses	20 028 705	15 398 520	19 218 072
Non-restricted equity			
Other non-restricted equity	-20 949 664	-9 048 618	18 860 805
Results for the period	-12 755 269	-5 320 863	-38 035 217
Total Equity	41 382 927	49 628 195	55 102 816
Long Term Liabilities			
Other long term liabilities	6 058 415	2 193 513	1 917 208
Non-current liability to group company	0		
Total Long Term Liabilities	6 058 415	2 193 513	1 917 208
Current Liabilities			
Accounts payable	7 399 636	5 153 442	8 888 418
Other current liabilities	772 247	1 030 317	3 401 023
Liabilities to credit institutions	9 286 113	7 171 018	5 505 968
Current payable to group company	0		
Accrued expenses and deferred income	9 683 364	6 289 673	6 673 362
Total current liabilities	27 141 360	19 644 449	24 468 771
Total liabilities	33 199 775	21 837 962	26 385 979
Total Equity and Liabilities	74 582 702	71 466 157	81 488 794

Changes in Equity – Dignitana Group, SEK

DIGNITANA GROUP	Q1 2020	Q1 2019	Full year 2019
Opening balance	55 102 816	54 965 116	54 965 116
New Share Issue	–		41 990 000
Unregistered Share Issue	–		
Issue expenses	–		-3 380 915
Translation difference on consolidation	-964 620	-16 058	-436 168
Results through the end of the period	-12 755 269	-5 320 863	-38 035 217
Closing balance	41 382 927	49 628 195	55 102 816

Statement of Cash Flows – Dignitana Group, SEK

DIGNITANA GROUP	Q1 2020	Q1 2019	Full year 2019
Operating Activities			
Operating income before financial items	-12 481 449	-4 710 070	-36 526 954
Adjustments for items not affecting cash flows	3 719 458	1 910 581	9 666 997
Interest received	20 082	838	102 589
Interest paid	-292 929	-560 508	-1 525 440
Income tax paid	0	-81 726	-425 058
	-9 034 838	-3 440 885	-28 707 866
Changes in inventories	599 369	-42 085	-3 082 569
Changes in other current receivables	56 135	-583 394	467 589
Changes in other current liabilities	-1 775 019	-2 222 371	3 988 327
Cash flows from operating activities	-10 154 353	-6 288 735	-27 334 519
Investing Activities			
Acquisition of fixed assets	-7 721 334	-2 751 065	-20 699 370
Cash flows from investing activities	-7 721 334	-2 751 065	-20 699 370
Financing activities			
New share issue	0	9 846 053	51 836 053
Issuance costs	0	-525 000	-3 905 915
Liabilities to credit institutions	7 019 717	-823 307	-2 764 662
Cash flows from financial activities	7 019 717	8 497 746	45 165 476
Cash flows in the period	-10 855 970	-542 054	-2 868 413
Cash and cash equivalents at start of the period	19 432 901	22 160 875	22 160 875
Translation difference on cash and cash equivalents	191 266	96 271	140 439
Cash and cash equivalents Period End	8 768 198	21 715 092	19 432 901

Income Statement – Dignitana AB, Parent Company, SEK

DIGNITANA AB, PARENT COMPANY	Q1 2020	Q1 2019	Full year 2019
Operating Income			
Revenue	7 746 448	6 220 499	27 114 785
Own work capitalized	0	0	0
Other income	1 084 564	869 820	1 846 817
Total Operating Income	8 831 012	7 090 319	28 961 602
Cost of Goods Sold			
Goods for Resale	-1 978 055	-1 096 358	-6 001 626
GROSS PROFIT	6 852 957	5 993 961	22 959 976
Expenses			
Operating expense	-9 443 926	-8 562 077	-33 682 777
Personnel expense	-541 781	-506 570	-1 573 393
Other operating expenses	-544 531	-12 228	-580 237
Total operating expenses	-10 530 238	-9 080 874	-35 836 407
Operating profit (loss) - EBITDA	-3 677 281	-3 086 913	-12 876 431
Depreciation of tangible and intangible assets	-3 643 951	-1 850 414	-9 950 466
Operating profit (loss) after depreciation - EBIT	-7 321 232	-4 937 327	-22 826 897
Result from financial investments			
Interest income and similar items	21 620	-	0
Interest expenses and similar items	-36 235	-349 023	-734 977
Total income from financial investments	-14 615	-349 023	-734 977
Net profit after financial items	-7 335 847	-5 286 350	-23 561 874
Corporate Taxes	0	0	0
Results for the Period	-7 335 847	-5 286 350	-23 561 874

Balance Sheet – Dignitana AB, Parent Company, SEK

DIGNITANA AB, PARENT COMPANY	Q1 2020	Q1 2019	Full year 2019
ASSETS			
FIXED ASSETS			
<u>Intangible assets</u>			
Capitalized expenses for development, net	21 059 301	20 820 171	22 561 837
<u>Tangible assets</u>			
Equipment, tools and installations, net	27 258 174	13 180 557	21 719 293
<u>Financial assets</u>			
Participations in group companies	522 094	522 094	522 094
Long Term Receivable from group companies	503 855	459 483	0
Total Fixed Assets	49 343 424	34 982 305	44 803 224
CURRENT ASSETS			
<u>Inventories and similar</u>			
Finished goods and goods for resale	5 122 339	6 350 621	8 473 678
Advance payment to suppliers	2 798 327	0	0
<u>Current Receivables</u>			
Accounts Receivable	1 150 937	2 536 381	1 277 591
Current Receivables from group companies	0	1 408 114	7 366 642
Current Tax Assets	327 651	6 825	314 450
Other Current Receivables	1 133 631	342 417	831 934
Prepaid expenses and accrued income	506 899	487 065	501 518
Cash and Bank Balances	2 531 495	17 085 444	17 116 918
Total Current Assets	22 863 055	28 216 866	35 882 731
Total Assets	72 206 479	63 199 172	80 685 955
EQUITY AND LIABILITIES			
Equity			
<u>Restricted equity</u>			
Share Capital			
(55 059 155 shares par value SEK 1, previous year 40 528 224)	55 059 155	48 599 155	55 059 155
Unregistered share capital	0	0	0
Fund for development expenses	20 028 705	15 398 520	19 218 072
Non-restricted equity			
Retained earnings	-76 192 341	-48 000 280	-51 819 834
Share premium reserves	83 594 504	48 064 504	83 594 504
Issue expense	-12 124 860	-8 743 945	-12 124 860
Results for the period	-7 335 847	-5 286 350	-23 561 874
Total Equity	63 029 316	50 031 605	70 365 163
Long Term Liabilities			
Other long term liabilities	0	1 027 530	0
Non-current liability to group company	0		
Total Long Term Liabilities	0	1 027 530	0
Current Liabilities			
Accounts payable	3 248 466	2 890 566	4 923 861
Other current liabilities	188 231	0	205 693
Liabilities to credit institutions	0	0	0
Current payable to group company	115 833	4 376 221	0
Accrued expenses and deferred income	5 624 633	4 873 250	5 191 238
Total current liabilities	9 177 163	12 140 037	10 320 792
Total liabilities	9 177 163	13 167 567	10 320 792
Total Equity and Liabilities	72 206 479	63 199 172	80 685 955

Policies for preparation of the financial report

Swedish Annual Accounts Act (1995:1554) and Swedish Accounting Standards Board General Recommendations BFNAR 2012:1 Annual reporting and consolidated financial statements.

Financial calendar

25 June 2020	Annual General Meeting
20 August 2020	Q2 Quarterly Report
19 November 2020	Q3 Quarterly Report
18 February 2021	2020 Year End Report

All financial reports are available at
www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktorgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.se
investorrelations@dignitana.com
www.dignitana.se

Certified Adviser

Erik Penser Bank AB
+46 (0) 8 463 83 00
certifiedadviser@penser.se
www.penser.se